Virtual Congress 2.0
POET Virtual Congress 2.0 Agenda
THURSDAY, OCTOBER 22
|9:00AM- 11:30AM MT||AM Session 1: Clinical Trials Design in Precision Oncology
Session Chair: Dr. Rosalyn Juergens
|9:00AM- 9:05AM||Welcome to the POET Virtual Congress 2.0 – Dr. Gwyn Bebb|
|9:05AM- 9:10AM||Welcome from the University of Calgary – Dr. Ed McCauley|
|9:10AM- 9:15AM||Welcome from Cancer Care Alberta – Dr. Paula Robson|
Lessons from biomarker-based clinical trials – Dr. David Hong
Novel marker discovery in the pre-clinical trials design – Dr. Charles Ricordel
Novel marker discovery moving into clinical trials design – Dr. Lori Kunkel
Panel: Hot Topic Debate
|10:55AM- 11:25AM||Questions & Discussion|
|11:25AM – 11:30AM||Closing Session Remarks – Dr. Gwyn Bebb|
|5:00PM- 8:00PM MT||PM Session 2: Immuno-Oncology and Precision Oncology
Session Chair: Dr. Doug Mahoney
|5:00PM- 5:05PM||Welcome to the POET Virtual Congress 2.0 – Dr. Pinaki Bose|
|5:05PM- 5:10PM||Welcome from University of Calgary and Alberta Health Services Oncology Department – Dr. Don Morris|
|5:10PM- 5:30PM||Oncolytic virus therapy – Dr. Doug Mahoney|
|5:30PM- 6:00PM||Innovations in CAR-T therapy – Dr. Brad Nelson|
|6:00PM- 6:20PM||Role of Cytokine Profiling in Immuno-Oncology – Dr. Faisal Khan|
|6:20PM- 6:40PM||Genes in Space: A Histological Perspective of Gene Expression in OSCC
– Dr. Pinaki Bose
|6:40PM- 7:00PM||Proteomics in precision oncology – Dr. Sorana Morrissy|
|7:00PM- 7:30PM||Panel: Hot Topic Debate
– How can the cost of immune-modulating interventions be reduced in the next 10 years?
– What is the best predictive biomarker for immunotherapy?
|7:30PM – 8:00PM||Questions & Discussions|
|8:00PM- 8:05PM||Closing Session Remarks – Dr. Pinaki Bose|
FRIDAY, OCTOBER 23
|9:00AM – 11:15AM MT||AM Session 3: Adoption of genomics for clinical decision making Across Canada
Session Chair: Dr. Steven Jones
|9:00AM- 9:05AM||Welcome to the POET Virtual Congress 2.0 – Dr. Pinaki Bose|
|9:05AM- 9:10AM||Welcome from Arnie Charbonneau Cancer Institute – Dr. Greg Cairncross|
|9:10AM- 9:30AM||Canadian NGS programs supporting access to profiling and clinical decision making – Dr. Steven Jones|
|9:30AM- 9:50AM||EXACTIS perspectives of supporting phase 1 clinical trials – Dr. Gerald Batist|
|9:50AM- 10:10AM||The economics of NGS in precision oncology – Dr. Dean Regier|
|10:10AM- 10:40AM||Panel: Hot Topic Debate
– What is the main challenge to the adoption of broad panel-based NGS testing in solid tumour patients?
– Is it necessary to build NGS testing infrastructure in Canada or is it best to send samples out of the country for testing?
– What level of RWE is required for justifying NGS adoption by health care providers?
– How can industry partner with (a) academia and (b)other private sector stakeholders to accelerate the adoption of NGS?
|10:40AM- 11:10AM||Questions & Discussions|
|11:10AM- 11:15AM||Closing Session Remarks – Dr. Pinaki Bose|
|5:00PM – 8:00PM MT||PM Session 4: Microbiome in Precision Oncology
Session Chair: Dr. Kathy McCoy
|5:00PM- 5:05PM||Welcome to the POET Virtual Congress 2.0 – Dr. Gwyn Bebb|
|5:05PM – 5:25PM||Microbiome in Oncology at the Calgary International Microbiome Centre – Dr. Kathy McCoy|
|5:25PM – 5:55PM||Pathogenesis of microbial biofilms in colorectal cancer – Dr. Julia Drewes|
|5:55PM – 6:25PM||Microbiome as a predictor of Hematopoietic Stem Cell Transplant Outcomes – Dr. Jonathan Peled|
|6:25PM – 6:55PM||Role of the microbiome in ovarian and endometrial cancers to lead to predictive and early detection tests, and intervention before cancer develops – Dr. Marina Walther-Antonio|
|6:55PM – 7:25PM||Panel: Hot Topic Debate
– Do we really believe that the microbiome influences treatment outcome?
– How do we design clinical trials that investigate modulating the microbiome as a cancer management intervention?
– Do antibiotics have a role to play in modulating the microbiome to improve cancer treatments?
|7:25PM – 7:55PM||Questions & Discussions|
|7:55PM – 8:00PM||Closing Remarks – Dr. Gwyn Bebb|